Medtech Giant Outperforms Expectations

  • Medtronic reported better-than-expected sales in Q4
  • Net income of $654 million or 49 cents per share
  • Adjusted earnings were $1.46 a share
  • Sales increased by 0.5% to $8.59 billion
  • Each segment posted mid-single digit or higher organic revenue growth
  • Organic revenue growth forecast for FY25: 4-5%
  • Adjusted EPS forecast for FY25: $5.40-$5.50

Medical technology company Medtronic has reported better-than-expected sales in its latest quarter, driven by growth across all four of its business segments. The company’s net income for the quarter ended April 26 was $654 million or 49 cents per share, down from $1.18 billion or 88 cents a share in the same period last year. Adjusted earnings came in at $1.46 per share, surpassing analyst estimates of $1.45 per share. Sales increased by 0.5% to $8.59 billion from $8.54 billion, beating expectations of $8.44 billion. CEO Geoff Martha attributed the strong performance to broad strength across all business segments, each posting mid-single digit or higher organic revenue growth. Medtronic has issued guidance for fiscal year 2025, forecasting organic revenue growth in the range of 4% to 5%, along with adjusted earnings per share between $5.40 and $5.50. Analysts polled by FactSet had expected $5.45 a share for the fiscal year.

Factuality Level: 10
Factuality Justification: The article provides accurate information about Medtronic’s financial performance, including net income, adjusted earnings, and sales figures, as well as guidance for the current fiscal year. It also includes quotes from the company’s CEO, Geoff Martha, discussing the growth across its four segments. The information is presented in a clear and concise manner without any apparent bias or misleading statements.
Noise Level: 3
Noise Justification: The article provides relevant financial information about Medtronic’s latest quarter results but lacks in-depth analysis and exploration of long-term trends or consequences of decisions. It also does not offer actionable insights or new knowledge for the reader.
Public Companies: Medtronic (MDT)
Key People: Geoff Martha (Chief Executive)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Medtronic’s stock price and medical technology industry
Financial Rating Justification: The article discusses Medtronic’s financial performance, including net income, adjusted earnings, sales growth, and guidance for the current fiscal year. This information can impact the company’s stock price and the overall medical technology industry.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no mention of an extreme event in this article.

Reported publicly: www.marketwatch.com